

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/070589 A3

(51) International Patent Classification:

C07F 9/09 (2006.01) **A61K 31/437** (2006.01)
C07D 471/04 (2006.01) **A61P 31/18** (2006.01)

(21) International Application Number:

PCT/US2006/047571

(22) International Filing Date:

13 December 2006 (13.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/750,247 14 December 2005 (14.12.2005) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Chung-Pin H.** [US/US]; c/o Bristol-Myers Squibb Co., 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **DIGIUGNO, Dawn** [US/US]; c/o Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, Connecticut 06492 (US). **GAO, Qi** [US/US]; c/o Bristol-Myers Squibb Co., 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **GU, Chong-Hui** [CN/US]; 217 Varick Road, Waban, Massachusetts 02468 (US). **LEVONS, Jaquan Kalani** [US/US]; c/o Bristol-Myers Squibb Co., 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **YANG, Bing-Shiou** [CN/US]; c/o Bristol-Myers Squibb Co., 1 Squibb Drive, New Brunswick, New Jersey 08903 (US).

(74) Agents: **CHAPMAN, Jennifer Chin** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

27 September 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRYSTALLINE FORMS OF 1-BENZOYL-4-[2-[4-METHOXY-7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1-[(PHOSPHONOOXY)METHYL]-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-1,2-DIOXOETHYL]-PIPERAZINE

(57) Abstract: The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).



WO 2007/070589 A3